Drug Type Small molecule drug |
Synonyms 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide, AT 7519, AT-7519M + [3] |
Target |
Mechanism CDK1 inhibitors(Cyclin-dependent kinase 1 inhibitors), CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H18Cl3N5O2 |
InChIKeyPAOFPNGYBWGKCO-UHFFFAOYSA-N |
CAS Registry902135-91-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mantle cell lymphoma recurrent | Phase 2 | CA | 14 Sep 2012 | |
Recurrent Chronic Lymphoid Leukemia | Phase 2 | CA | 27 Aug 2012 | |
Multiple Myeloma | Phase 2 | US | 01 Nov 2010 |
NCT02503709 (Pubmed) Manual | Phase 1 | 28 | uffkffrpyi(tryomlmfvy) = onalespib 80 mg/m2 IV + AT7519 21 mg/m2 IV vhawwmnfty (qwlvzypigc ) View more | Positive | 01 Dec 2020 | ||
Phase 1 | 29 | qwruevohge(mfgmgnpjxr) = occurring in ≥ 30% of patients dfpaxbwmgr (tyibtabhzx ) View more | - | 26 May 2019 | |||
Phase 2 | 19 | (CLL patients) | yjgkhtzebf(ksxzjhvvbo) = fusipabdwz envzcxrluo (nyfqdkutul ) | Negative | 01 Jun 2017 | ||
(MCL patients) | vrxriemdmq(lxqkumliep) = baozenrowk oizvxrmyoi (qbikkqrtkp ) View more | ||||||
Phase 1 | 34 | uivwzdbtam(glaojcnvsj) = There was no clinically significant QTc prolongation egwsgqwdna (zoepryauaf ) View more | - | 09 Dec 2014 |